Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapesTargeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes, Published online: 14 November 2017; doi:10.1038/nrclinonc.2017.175NatureArticleSnippet(type=short-summary, markup=The receptor-tyrosine kinase RET has been identified as a potentially actionable driver of oncogenesis. Several multikinase inhibitors with activity against RET have been explored in the clinic, but have only modest efficacy in patients with thyroid cancers, mostly in those with RET mutations, or RET-rearranged lung cancers. Herein, the authors outline the aberrations in RET that contribute to tumorigenesis, review the current clinical data for inhibitors of this kinase, and discuss whether the limited clinical success achieved with these agents to date is attributable to the intractability of RET as a drug target or the lack of highly specific RET inhibitors., isJats=true)

Source: Nature Clinical Practice Oncology - November 14, 2017 Category: Cancer & Oncology Authors: Alexander Drilon Zishuo I. Hu Gillianne G. Y. Lai Daniel S. W. Tan Source Type: research